Related Experiment Video
Updated: Dec 26, 2025
11:05
Production and Administration of Therapeutic Mesenchymal Stem/Stromal Cell MSC Spheroids Primed in 3-D Cultures Under Xeno-free Conditions
Published on: March 18, 2017
12.4K
Recent advances in understanding mesenchymal stromal cells.
Erika Rendra1, Eleonora Scaccia1, Karen Bieback1,2,3
1Institute of Transfusion Medicine and Immunology, Mannheim Institute of Innate Immunoscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, 68167, Germany.
F1000Research
|March 10, 2020
Summary
Mesenchymal stromal cells (MSCs) show promise in therapy but clinical results lag preclinical findings. Optimizing MSC manufacturing, understanding mechanisms, and improving potency assays are key for successful clinical translation.
Area of Science:
- Cellular therapy
- Regenerative medicine
- Biotechnology
Background:
- Mesenchymal stromal cells (MSCs) are extensively studied for cellular therapy due to ease of isolation and expansion.
- Despite early marketing authorization, MSC clinical efficacy often falls short of preclinical promises.
- Bridging the gap between preclinical and clinical outcomes requires a thorough evaluation of MSC manufacturing and function.
Purpose of the Study:
- To review critical factors influencing Mesenchymal stromal cell (MSC) therapy success.
- To identify challenges and opportunities for improving MSCs for clinical applications.
- To explore MSC mechanisms of action and their translation into potency assays.
Main Methods:
- Review of preclinical and clinical data on Mesenchymal stromal cell (MSC) therapy.
- Analysis of factors including tissue origin, culture conditions, immunogenicity, and dosing.
- Examination of MSC mechanisms of action and development of potency assays.
Main Results:
- Discrepancies between preclinical and clinical Mesenchymal stromal cell (MSC) results highlight manufacturing and functional complexities.
- Optimizing tissue source, culture methods, immune compatibility, and delivery strategies are crucial for enhanced therapeutic outcomes.
- Understanding MSC mechanisms is vital for developing reliable potency assays.
Conclusions:
- Further research into Mesenchymal stromal cell (MSC) manufacturing, mechanisms, and quality control is essential for clinical translation.
- Future therapeutic products may involve cell-based or cell-derived approaches.
- Addressing the bench-to-bedside gap is critical for realizing the full potential of MSCs in regenerative medicine.
